Paysign (PAYS)
Runs prepaid payment programs for plasma centers, drugmakers, and healthcare clients.
Something off on this page? Send us feedback.
Manages prepaid-card and software programs for donor compensation, pharmaceutical patient affordability, and other business disbursements. Revenue is reported as one segment, with recent operations centered on plasma and pharma workflows in the United States.
Built around prepaid-card issuing, processing, and program management, the business serves plasma collection centers, pharmaceutical patient-affordability programs, and smaller corporate disbursement uses. Product names in context include patient affordability solutions, disbursement solutions, Paysign Premier digital banking, incentive solutions, and Apherion donor-management software.
Operations are concentrated in the United States, with headquarters in Henderson, Nevada. The latest filing reports one operating and reportable segment, so product-line economics are visible mainly through plasma, pharma, and other revenue-line disclosures rather than separate segment reporting.
Execution depends on regulated funds flow, payment-network rules, healthcare copay-assistance requirements, data security, and integration of the Gamma donor-engagement assets.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 15, 2026 | Lake Street | Reiterate | Rating: —Target: $13 | Target: $15 |
| Aug 11, 2026 | Barrington | Target | Target: $11 | Target: $15 |
| Aug 6, 2026 | DA Davidson | Reiterate | Rating: —Target: $9 | Target: $12 |
| Aug 6, 2026 | Lake Street | Reiterate | Rating: —Target: — | Target: $13 |
| Aug 3, 2026 | Barrington | Target | Target: — | Target: $11 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $27.4M · Total debt $5.7M · Total assets $317.0M · Shareholders' equity $60.2M
- Revenue
- $28.3M
- Operating income
- $7.0M
- Net income
- $6.8M
No dividends on record.
| Institutions | ≈ 53.67% | 30.30M shares | |
|---|---|---|---|
| 140 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 35.01% | 19.77M shares | |
| 13 holders · as of Sep 17, 2026 | |||
| Other | ≈ 11.32% | 6.39M shares | |
| remainder | |||
56.46M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Mark NewcomerInsiderdirector, 10 percent owner, officer: CEO | 16.23% | 9.16M | filed Aug 7, 2026 |
Topline Capital Management, LLCInstitution | 8.22% | 4.64M | as of Jun 30, 2026 |
Daniel SpenceInsider10 percent owner | 7.61% | 4.30M | filed Mar 25, 2025 |
BlackRock, Inc.Institution | 5.45% | 3.08M | as of Jun 30, 2026 |
Michael C. NgoInsiderofficer: Chief Innovation Officer | 4.98% | 2.81M | filed Sep 10, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 16, 2026 | Joan M. Herman | director, officer: EVP, Operations | −38,900 | $11.74 |
| Sep 15, 2026 | Joan M. Herman | director, officer: EVP, Operations | −21,004 | $12.38 |
| Sep 9, 2026 | Michael C. Ngo | officer: Chief Innovation Officer | −79,925 | $12.74 |
| Sep 8, 2026 | Michael C. Ngo | officer: Chief Innovation Officer | −70,075 | $12.85 |
| Feb 3, 2026 | Matthew Baker Turner | officer: PRES., PATIENT AFFORDABILITY | −15,057 | $4.16 |
- McKesson
Access and affordability platform for biopharma programs
- Haemonetics
Plasma-center software and donor workflow systems
- IQVIA
Global patient-support and affordability services
- Cencora
Manufacturer services for copay and patient access
- Green Dot
Prepaid, paycard, BaaS, and disbursement platform
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Paysign | $12.57 | −0.48% | $706.1M | 49.0 | 35.2 | 7.0 | +48.1% |
| McKesson | $895.11 | +0.97% | $103.79B | 23.7 | 19.3 | 0.3 | +7.7% |
| Haemonetics | $109.21 | +0.44% | $4.94B | 53.3 | 19.8 | 3.7 | +5.6% |
| IQVIA | $271.78 | +0.70% | $44.42B | 33.5 | 20.0 | 2.6 | +8.7% |
| Cencora | $317.15 | +0.21% | $61.58B | 23.5 | 16.3 | 0.2 | +5.1% |
| Green Dot | $13.24 | +0.65% | $745.3M | — | 8.3 | 0.3 | +17.3% |
| Median | 28.6 | 19.3 | 0.3 | +7.7% |